Ainos (NASDAQ:AIMD) Issues Earnings Results

Ainos (NASDAQ:AIMD) announced its quarterly earnings results on Thursday. The company reported ($0.64) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.00 million during the quarter.

Ainos Stock Performance

Shares of NASDAQ:AIMD traded down $0.37 during trading on Friday, hitting $2.21. The company’s stock had a trading volume of 76,533 shares, compared to its average volume of 733,606. Ainos has a 12 month low of $2.00 and a 12 month high of $5.00. The firm has a market cap of $10.54 million, a price-to-earnings ratio of -0.44 and a beta of 2.22. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.88 and a quick ratio of 2.61. The company has a 50-day moving average of $3.51 and a 200-day moving average of $3.16.

Insider Buying and Selling

In other news, major shareholder Carbon Nano Technology Taiwan sold 7,000 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $3.59, for a total value of $25,130.00. Following the transaction, the insider owned 1,037,206 shares of the company’s stock, valued at approximately $3,723,569.54. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.79% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ainos stock. Two Sigma Investments LP bought a new position in Ainos, Inc. (NASDAQ:AIMD) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned approximately 0.48% of Ainos at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

AIMD has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ainos in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Ainos from a “sell” rating to a “hold” rating in a research report on Friday, September 5th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.